From Scientific Research

What the REDUCE-IT trial studied, what it found, and why a prescription-medicine result is not a claim for every fish oil supplement.

What did REDUCE-IT study?

REDUCE-IT studied icosapent ethyl, a prescription form of EPA. Participants were receiving statin therapy, had elevated triglycerides and had cardiovascular disease or diabetes with additional risk factors.

Stock healthcare photograph, not the REDUCE-IT trial team

The trial compared 4 grams per day of icosapent ethyl with placebo. This describes the research protocol, not a recommended supplement dose.

Understand the result

The trial reported a hazard ratio of 0.75 for its primary composite cardiovascular endpoint, commonly described as a 25% relative reduction in hazard. Events occurred in 17.2% of the treatment group and 22.0% of the placebo group over a median follow-up of 4.9 years.

REDUCE-IT prescription-medicine trial: primary composite endpoint events occurred in 17.2% with icosapent ethyl and 22.0% with placebo, over a median 4.9 years. Not a result for ordinary fish oil.

That is a 4.8 percentage-point absolute difference. The endpoint combined cardiovascular death, heart attack, stroke, coronary revascularisation and hospitalisation for unstable angina; it was not a 25% reduction in every individual outcome. Hospitalisation for atrial fibrillation or flutter was more frequent in the treatment group. The FDA label also warns of increased bleeding risk.

Keep the evidence with the treatment

The findings apply to the studied medicine and patient population. They do not establish that an over-the-counter fish oil supplement—or a Ciyive product—produces the same benefit.

Broader omega-3 trials vary in formulation, dose and participants, so their results should not be combined into a universal product promise. Discuss treatment decisions with your clinician.